Zynex Inc. (OTCMKTS:ZYXI) – Research analysts at B. Riley lowered their Q3 2019 earnings estimates for Zynex in a report released on Wednesday, May 1st, Zacks Investment Research reports. B. Riley analyst M. Wiesenberger now anticipates that the company will post earnings of $0.06 per share for the quarter, down from their previous forecast of $0.07. B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for Zynex’s Q4 2019 earnings at $0.07 EPS.
Several other research firms also recently weighed in on ZYXI. Zacks Investment Research upgraded shares of Zynex from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Saturday, March 2nd. ValuEngine upgraded shares of Zynex from a “hold” rating to a “buy” rating in a research report on Friday, February 8th.
Zynex (OTCMKTS:ZYXI) last issued its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. Zynex had a net margin of 33.33% and a return on equity of 152.81%. The company had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $8.45 million.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in shares of Zynex in the 1st quarter worth $215,000. WealthTrust Axiom LLC purchased a new position in shares of Zynex in the 1st quarter worth $132,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Zynex in the 1st quarter worth $118,000. Sigma Planning Corp purchased a new position in shares of Zynex in the 1st quarter worth $63,000. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Zynex in the 1st quarter worth $45,000. 0.05% of the stock is owned by institutional investors.
In related news, CEO Thomas Sandgaard sold 15,403 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $7.50, for a total transaction of $115,522.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daniel J. Moorhead sold 25,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $7.17, for a total transaction of $179,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 380,487 shares of company stock worth $2,181,725 over the last 90 days.
Zynex Company Profile
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Article: What is Elliott Wave theory?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.